Glenmark and Sun Pharma introduce nintedanib generics in India at a fraction of the innovator product’s price, vying for a share of the IPF market where pirfenidone currently holds sway.

Teva, Sun and the AAM are among those urging the CMS to rescind its proposal to reimburse Part B drugs approved under section 505(b)(2) as multiple source products. The proposal would target one relatively small but growing part of Medicare Rx spending and reflects CMS’ ongoing concern with fast rising costs in the program.

Despite the average trade price of ciprofloxacin shooting up in September, no UK price concessions were granted by the DHSC.

The CMA has launched an investigation into Essential Pharma regarding its lithium-based treatment, Priadel. As an interim measure, the company has been advised to continue supplying the bipolar disorder treatment to UK patients.

With the aim of lowering prices and improving access to certain prescription drugs, the US FDA and HHS have decided to allow imports from Canada. To enable this, the FDA has finalized the rule allowing importation and issued accompanying guidance.

Moxonidine topped our table of Biggest Risers for the second month in a row, as UK prices that had doubled in July accelerated even more rapidly in August.